ARA-290
Tissue & recoveryAlso known as Cibinetide, pHBSP
Evidence tier
Regulator-reviewed human evidence
2 human trials · 2 reviews
- Researched since
- 2012
- Publications
- 60
- Mean purity
- 99.7%
- Vendors listing
- 12
Ascension Peptides shows the highest mean assayed purity for ARA-290 at 99.9% across 1 lot record. Purity figures below come from the certificates named in each row.
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2012 — 14 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
60 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.7% across 6 certificates
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
±0.26 pts purity across lots, mean label deviation 6.1%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
12 of 12 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
6 of 6 certificates from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is ARA-290?
An eleven–amino-acid peptide derived from the structure of erythropoietin, designed to engage tissue-protective signalling without the red-blood-cell effects of erythropoietin.
Studied in published research for neuropathic pain and tissue protection.
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
Investigated in human trials for neuropathic conditions such as sarcoidosis-associated small-fibre neuropathy. PepIndex does not evaluate clinical significance and does not describe administration.
- Editorial — Molecular medicine (Cambridge, Mass.) (2013)
Peer-reviewed article indexed in PubMed, published in Molecular medicine (Cambridge, Mass.) (2013).
- ARA 290 for treatment of small fiber neuropathy in sarcoidosis — Expert opinion on investigational drugs (2014)
Peer-reviewed article indexed in PubMed, published in Expert opinion on investigational drugs (2014).
- The time to develop treatments for diabetic neuropathy — Expert opinion on investigational drugs (2021)
Peer-reviewed article indexed in PubMed, published in Expert opinion on investigational drugs (2021).
- Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression — Brain, behavior, and immunity (2022)
Peer-reviewed article indexed in PubMed, published in Brain, behavior, and immunity (2022).
- ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception — Peptides (2016)
Peer-reviewed article indexed in PubMed, published in Peptides (2016).
- A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema — Journal of clinical medicine (2020)
Peer-reviewed article indexed in PubMed, published in Journal of clinical medicine (2020).
- Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis — Scientific reports (2017)
Peer-reviewed article indexed in PubMed, published in Scientific reports (2017).
- Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand — Transplantation (2020)
Peer-reviewed article indexed in PubMed, published in Transplantation (2020).
Indexed studies4 human-evidence of 4
- Managing fatigue in sarcoidosis - A systematic review of the evidence — Systematic review, 2017
Fatigue is a common manifestation of sarcoidosis, often persisting without evidence of disease activity. First-line therapies for sarcoidosis have limited effect on fatigue. This review aimed to assess the treatment options targeting sarcoidosis-associated fatigue. Medline and Web of Science were searched in November 2015; the bibliographies of these papers, and relevant review papers, were also searched. Studies were included if they reported on the efficacy of interventions…
- The time to develop treatments for diabetic neuropathy — Systematic review, 2021
Diabetic neuropathy is a multifaceted condition affecting up to 50% of individuals with long standing diabetes. The most common presentation is peripheral diabetic sensory neuropathy (DPN). We carried out a systematic review of papers dealing with diabetic neuropathy on Pubmed in addition to a targeted Google search.Search terms included small fiber neuropathy,diffuse peripheral neuropathy, quantitative sensory testing, nerve conduction testing, intra-epidermal nerve fiber de…
- Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study — Human — controlled trial, 2012
ARA 290 (a peptide designed to activate the innate repair receptor that arrests injury and initiates cytoprotection, antiinflammation and healing) reduces allodynia in preclinical neuropathy models. We studied the safety and efficacy of ARA 290 to reduce symptoms of small fiber neuropathy (SFN) in patients with sarcoidosis. A total of 22 patients diagnosed with sarcoidosis and symptoms of SFN were enrolled in a double-blind, placebo-controlled exploratory trial consisting of …
- Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain — Human — controlled trial, 2017
Sarcoidosis frequently is complicated by small nerve fiber loss (SNFL), which can be quantified using corneal confocal microscopy (CCM). Prior studies suggest that the innate repair receptor agonist cibinetide reverses corneal nerve loss. This phase 2b, 28-day, randomized trial of 64 subjects with sarcoid-associated SNFL and neuropathic pain assessed the effect of cibinetide on corneal nerve fiber area (CNFA) and regenerating intraepidermal fibers (GAP-43+) as surrogate endpo…
Evidence digest
What the research on ARA-290 actually shows
The indexed literature on ARA-290 includes human clinical or observational records (4 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether ARA-290 is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
3 things the literature does not establish →
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.
Vendor comparison
| Vendor | Score here | Price / mg | Certificates | Mean purity | Label deviation | Get it |
|---|---|---|---|---|---|---|
| Ascend ScienceISO/IEC 17025 | 90.291% | — | 1 | 99.4% | 6.2% | |
| American PeptidesISO/IEC 17025 | 89.8100% | $5.13 (84%) | 1 | 99.9% | 2.4% | |
| PeptidePlugs | 89.790% | — | 1 | 99.8% | 4.3% | |
| Northline LabsISO/IEC 17025 | 79.293% | $8.00 (130%) | 0 | — | — | |
| Good Science Bio | 79.275% | $2.50 (41%) | 0 | — | — | |
| Licensed Peptides | 7789% | $5.94 (97%) | 0 | — | — | |
| NeuroLabs Research | 75.986% | $6.80 (111%) | 0 | — | — | |
| Ascension Peptides | 75.386% | $7.00 (114%) | 1 | 99.9% | 0.1% | |
| Modern AminosISO/IEC 17025 | 74100% | — | 1 | 99.9% | 17.0% | |
| Simple Peptide | 7489% | — | 1 | 99.3% | 6.6% | |
| BioLongevity Labs | 71.674% | $6.33 (103%) | 0 | — | — | |
| Mile High Compounds | 67.894% | $5.00 (82%) | 0 | — | — |
Certificate records
| Vendor | Lot | Tested | Lab | Labeled | Assayed | Discrepancy | Purity | Source |
|---|---|---|---|---|---|---|---|---|
| Ascend Science | AS-ARA10-2 | Kovera Labs | 10 mg | 10.62 mg | 6.2% | 99.4% | Vendor-published | |
| American Peptides | ARA290-0616 | Bioviridian Inc. | 16 mg | 16.39 mg | 2.4% | 99.9% | Vendor-published | |
| PeptidePlugs | 142-01-DK | Freedom Diagnostics Testing | 10 mg | 10.43 mg | 4.3% | 99.8% | Vendor-published | |
| Modern Aminos | BX-P-D7N6 | Vanguard Laboratory | 10 mg | 11.7 mg | 17.0% | 99.9% | Vendor-published | |
| Simple Peptide | ARA16-052026-7 | Analysis FreedomDiagnostics | 16 mg | 17.05 mg | 6.6% | 99.3% | Vendor-published | |
| Ascension Peptides | 53-12250129 | MZ Biolabs | 10 mg | 9.99 mg | 0.1% | 99.9% | Vendor-published |